𝔖 Bobbio Scriptorium
✦   LIBER   ✦

ZD1839 (Gefitinib, ‘Iressa’), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma

✍ Scribed by Fuminori Teraishi; Shunsuke Kagawa; Takanori Watanabe; Yasuhisa Tango; Takeshi Kawashima; Tatsuo Umeoka; Masahiko Nisizaki; Noriaki Tanaka; Toshiyoshi Fujiwara

Book ID
116465753
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
444 KB
Volume
579
Category
Article
ISSN
0014-5793

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antitumor activity of the selective epid
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa® (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo
✍ Ichiro Naruse; Tohru Ohmori; Yoko Ao; Hisao Fukumoto; Toshio Kuroki; Masatomo Mo 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 216 KB 👁 1 views

## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell

Additive antitumor effects of the epider
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro
✍ Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Danilo Millimaggi; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 618 KB

## Abstract Progression from an androgen‐dependent to an androgen‐independent state often occurs in patients with prostate cancer (PCa) who undergo hormonal therapy. We have investigated whether inhibition of the epidermal growth factor receptor (EGFR) signaling pathway affects the antitumor effect